. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Pain. 2014 Sep 19;155(12):2560–2567. doi: 10.1016/j.pain.2014.09.016

Table 1. Cytokine levels for animals treated concomitantly with IB-MECA.

Concurrent IB-MECA retains efficacy in modulating spinal pro-/anti-inflammatory cytokines with paclitaxel-treatment.

IB-MECA (0.1 mg/kg/d; D0–4) given 15–20 minutes prior to paclitaxel (D0, 2, 4, and 6) effectively prevented the increase in pro-inflammatory cytokines (TNF-α, IL-1β) and increased the anti-inflammatory cytokine IL-10 as measured on D25. Results are expressed as mean ± SD for n=6 and analyzed by one-way ANOVA with Dunnett’s post hoc comparisons.

Treatment	TNF-α (pg/mg protein)		IL-1β (pg/mg protein)		IL-10 (pg/mg protein)
Treatment	Mean ± SD	95% CI	Mean ± SD	95% CI	Mean ± SD	95% CI

Vehicle	27.1 ± 5.2	21.6 – 32.5	40.0 ± 13.4	26.0 – 54.0	110.9 ± 19.5	90.4 – 131.3

Paclitaxel	40 ± 8.3^*	31.5 – 49.0	73.1 ± 13.8^*	58.6 – 87.6	94.6 ± 19.4	74.3 – 114.9

P+IB-MECA	26 ± 4.6^**	22.1 – 31.8	40.5 ± 12.6^**	27.3 – 53.7	146.9 ± 13.1	133.2 – 160.7^**

P<0.05 vs. Vehicle;

^**

P<0.05 vs. Paclitaxel